Renal diseases and Hemodialysis
Torii mainly markets products related to hemodialysis in the area of renal diseases and Hemodialysis.
Riona Tablets (a hyperphosphatemia drug) that Torii launched in May 2014 is an oral drug for hyperphosphatemia for patients with CKD (dialysis/ peritoneum/conservative phase of kidney disease).
REMITCH CAPSULES (an oral antipruritic drug) that Torii launched in March 2009 is an oral selective opioid kappa receptor agonist for pruritus that is resistant to existing therapies (existing antipruritic drugs are not sufficiently effective) of patients on dialysis, and is highly evaluated as a therapeutic agent for pruritus for patients on dialysis. REMITCH OD Tablets that Torii launched in June 2017, can be taken with or without water and therefore is convenient for patients whose swallowing capabilities have deteriorated or those who have restrictions on water intake, and is expected to lead to improved drug intake compliance.
Torii launched KAYEXALATE DRYSYRUP in February 2011 for improving the ease of taking KAYEXALATE Powder (agent for hyperkalemia). KAYEXALATE DRYSYRUP flavored with apple improves patients’ compliance and is highly evaluated in dialysis facilities.
- Riona Tablets
- Therapeutic agent for hyperphosphatemia
- Oral therapeutic agent for pruritus
- Therapeutic agent for hyperkalemia
In the area of skin diseases, Torii markets products related to the treatment of skin diseases such atopic dermatitis and tinea pedis.
ANTEBATE has three dosage forms: ointment, cream, and lotion. It improves the symptoms of skin diseases such as atopic dermatitis and contact dermatitis by reducing inflammation. The availability of three dosage forms allows users to use each one depending on the disease, site, and symptoms. In addition, Torii has made efforts to improve the quality of life (QOL) of patients by improving the quality of the base and ease of use, and ANTEBATE is highly evaluated.
- Topical corticosteroid
In the area of allergens, Torii has produced and marketed products for the diagnosis and treatment of allergic diseases for about half a century, and currently markets 151 products for the diagnosis and treatment of 85 antigens as of June 2018.
CEDARTOLEN ® SUBLINGUAL DROP - Japanese Cedar Pollen launched by Torii in October 2014 is the first sublingual immunotherapy drug for Japanese Cedar Pollen.
CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets launched by Torii in June 2018 is the sublingual immunotherapy drug for Japanese Cedar Pollen and the first regulatory approved sublingual tablet available for adult and pediatric patients in Japan.
MITICURE ® House Dust Mite Sublingual Tablets launched by Torii in December 2015 is an allergen immunotherapy tablet for house dust mite allergy, for the indication of allergic rhinitis. In addition, this drug was approved an additional dosage and administration for pediatric indication in February 2018.
- CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen
- Sublingual immunotherapy drug
- CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets
- Allergen immunotherapy tablet
- MITICURE® House Dust Mite Sublingual Tablets
- Allergen immunotherapy tablet